Recombinant botulinum toxin type A - JHM Biopharma
Alternative Names: Eveotox; JHM-03Latest Information Update: 29 Apr 2025
At a glance
- Originator JHM BioPharma (Tonghua)
- Class Antispastics; Bacterial toxins; Botulinum toxins; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Acetylcholinesterase inhibitors; Glutamate antagonists; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Glabellar lines; Muscle spasticity
Most Recent Events
- 22 Apr 2025 JHM BioPharma plans a phase III trial for Glabellar lines in China (IM) (NCT06937944)
- 09 Sep 2024 JHM BioPharma completes phase I/II clinical trials in Glabellar lines in China (IM) (NCT06199336)
- 09 Sep 2024 JHM BioPharma plans phase-Ib/II trial for Muscle spasticity in October 2024 (NCT06584240)